Palvella Therapeutics PVLA
NASDAQ PVLA
$157.24 +1.77 (+1.14%)
As of: Sep 4, 2026 · 3:59 PM EDT

Palvella Therapeutics (PVLA) Change in Receivables (2014 - 2025)

Palvella Therapeutics (PVLA) posted quarterly Change in Receivables of -$29000.0 for Q4 2025, up 91.9% quarter-over-quarter from -$358000.0 in Q1 2025.

Analysis

Palvella Therapeutics (PVLA) Change in Receivables (2014 - 2025) Analysis & Trends

Palvella Therapeutics (PVLA) has reported Change in Receivables for 4 consecutive years, with -$29000.0 the latest figure, recorded in Q4 2025.

  • In Q4 2025, Change in Receivables changed N/A year-over-year to -$29000.0; the TTM figure through Dec 2025 stood at -$387000.0 (changed N/A YoY), while the FY2025 annual figure was -$387000.0, changed N/A from the prior year.
  • Change in Receivables rose to -$29000.0 in Q4 2025 per PVLA's latest filing, from -$358000.0 in the prior quarter.
  • Across five years, Change in Receivables topped out at -$29000.0 in Q4 2025 and bottomed at -$358000.0 in Q1 2025.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Change in Receivables (Qtr)
1 Vertex Pharmaceuticals 138.47 Bn 130.62 Bn 2.84 Bn 140.20 Mn
2 Regeneron Pharmaceuticals 85.18 Bn 77.19 Bn 3.93 Bn 838.50 Mn
3 Argenx Se 63.38 Bn 58.19 Bn 1.37 Bn -
4 Moderna 58.09 Bn 52.95 Bn 52.00 Mn -53.00 Mn
5 Revolution Medicines 44.33 Bn 44.33 Bn - -
6 BeOne Medicines 40.02 Bn 34.92 Bn 1.53 Bn 117.58 Mn
7 Alnylam Pharmaceuticals 35.57 Bn 32.27 Bn 992.69 Mn 31.60 Mn
8 Royalty Pharma 28.45 Bn 27.61 Bn - -
9 Insmed 27.48 Bn 26.32 Bn 358.27 Mn 37.16 Mn
10 Palvella Therapeutics 2.24 Bn 1.93 Bn - -
Historic Data

Historic Data

Download Data
DateValue
Dec 31, 2025 -29,000.00
Mar 31, 2025 -358,000.00
Dec 31, 2017 12.13 Mn
Sep 30, 2017 -44.15 Mn
Jun 30, 2017 46.50 Mn
Mar 31, 2017 -19,328.00
Mar 31, 2016 68,870.00
Sep 30, 2014 -474,418.00
Jun 30, 2014 -68,553.00
Mar 31, 2014 -479,677.00